|
Video: What is a Stock Split?
|
|
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world.. In China, Co.'s first commercial product, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in our pipeline include: CNCT19, which is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. According to our CASI split history records, CASI Pharmaceuticals has had 1 split. | |
|
CASI Pharmaceuticals (CASI) has 1 split in our CASI split history database. The split for CASI took place on June 02, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of CASI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as CASI Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CASI split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CASI Pharmaceuticals shares, starting with a $10,000 purchase of CASI, presented on a split-history-adjusted basis factoring in the complete CASI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$18.20 |
|
End price/share: |
$3.00 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-83.52% |
|
Average Annual Total Return: |
-16.50% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,648.46 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
06/02/2022 | 1 for 10 |
|
|